MK-3475/BCG in High Risk Superficial Bladder Cancer

Summary

This is a single center Phase I safety and efficacy study of MK-3475 therapy used in combination with bladder infused BCG treatment for patients, 18 years or older, with high risk superficial bladder cancer (cancer not yet involving the muscle of the bladder wall) who have had removal of their bladder tumor. Patients will be enrolled to a single treatment group of a fixed dose of MK 3475 and BCG.

Timeline

Start

2015-06

Primary completion

2021-11-18

Completion

2023-03-27

Publications

• Jamil ML, Deebajah M, Sood A, Robinson K, Rao K, Sana S, Alanee S. Protocol for phase I study of pembrolizumab in combination with Bacillus Calmette-Guerin for patients with high-risk non-muscle invasive bladder cancer. BMJ Open. 2019 Jul 17;9(7):e028287. doi: 10.1136/bmjopen-2018-028287.

Drugs

Indications